McMinn Rachel
Chief Executive Officer
McMinn Rachel has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Oct 2, 2026.
On the most recent filing, McMinn Rachel is listed as Chief Executive Officer at Neurogene Inc. Inside the rolling window, McMinn Rachel reported no open-market purchases and 1 open-market sale totaling $74K in NGNE.
Companies traded
Other insiders at NGNE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$74K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has McMinn Rachel made?
McMinn Rachel has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does McMinn Rachel trade?
McMinn Rachel has filed SEC Form 4 disclosures for 1 company, including NGNE.
When was McMinn Rachel's most recent SEC Form 4 filing?
McMinn Rachel's most recent SEC Form 4 filing on Tracefour is dated Oct 2, 2026.
What is McMinn Rachel's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, McMinn Rachel is listed as Chief Executive Officer.
What is McMinn Rachel's total buy and sell value in the current window?
Inside the rolling retention window, McMinn Rachel bought $0 and sold $74K based on SEC Form 4 filings.
What was McMinn Rachel's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,352 NGNE shares on 2026-03-26, worth $74K, per SEC Form 4 filings.